Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to ...

Boehringer’s Phase III data show survodutide cuts visceral & liver fat and drives weight loss, boosting its obesity/MASLD ...

Company announcement No. 21 / 2026Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and ...

Northwestern Medicine scientists led by Joseph Bass, MD, Ph.D., the Charles F. Kettering Professor of Endocrinology and Metabolism and director of the Center for Diabetes and Metabolism, have ...

Consuming a high-fat diet can lead to a variety of health problems—not only weight gain but also an increased risk of diabetes and other chronic diseases. At the cellular level, hundreds of changes ...

A medication long used to help people breathe may soon help protect the liver as well. Researchers at the Medical University ...

CINCINNATI—Cardiac researchers at the University of Cincinnati (UC) have found a new cellular pathway that could help in developing therapeutic treatments for obesity-related disorders, like diabetes ...

Eating late at night may therefore lead to higher blood sugar because the body, including the liver, processes glucose less ...

A new study suggests using body mass index alone may miss many people with the disease, but the findings come with caveats.